Loading company
Marker Therapeutics, Inc.
MRKR · Nasdaq · ·
$1.10-2.2%Sep 29 close
- 1M
- -19.7%
- 6M
- -11.3%
- 1Y
- +23.2%
- 5Y
- -94.0%
MRKR · Nasdaq · ·
$1.10-2.2%Sep 29 close
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $751.7K | $349.1K | +115.32% |
| Profit | -$1.8M | -$4M | +54.52% |
| Profit per share | -$0.09 | -$0.29 | +68.97% |
| Free Cash Flow | -$5.6M | -$4.3M | -31.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Marker Therapeutics, Inc. has no earnings call transcript available.
“In 2025, we continued to advance MT-601, our lead Multi-Antigen Recognizing (MAR)-T cell therapy, and generated highly encouraging clinical data from our ongoing Phase 1 APOLLO study,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Marker Therapeutics, Inc.’s Item 2.02 8-K filed March 19, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.